Shield TherapeuticsSTU:1JS EV-to-FCF is -28.91 as of Jun. 27, 2026. The stock has 5 warning signs investors should review. Among 562 Drug Manufacturers companies, Shield Therapeutics ranks worse than 177935.77% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Shield Therapeutics's Enterprise Value is €92.02 Mil.
Shield Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €-3.18 Mil. Therefore, Shield Therapeutics's EV-to-FCF for today is -28.91.
The historical rank and industry rank for Shield Therapeutics's EV-to-FCF or its related term are showing as below:
STU:1JS'
s EV-to-FCF Range Over the Past 10 Years
Min: -67.18 Med: -7.74 Max: 0.03
Current: -30.73
During the past 12 years, the highest EV-to-FCF of Shield Therapeutics was 0.03. The lowest was -67.18. And the median was -7.74.
STU:1JS's EV-to-FCF is ranked worse than 100% of 562
companies
in the Drug Manufacturers industry
Industry Median: 20.11
vs STU:1JS: -30.73
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Shield Therapeutics's PE Ratio (TTM) for today is calculated as:
Shield Therapeutics's share price for today is €0.068.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Shield Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.018.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Shield Therapeutics EV-to-FCF Related Terms
Shield Therapeutics EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Shield Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Shield Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shield Therapeutics EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shield Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Shield Therapeutics's EV-to-FCF falls into.
Shield Therapeutics's current Enterprise Value is €92.02 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Shield Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €-3.18 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shield Therapeutics (STU:1JS) has a EV-to-FCF of -28.91 as of Jun. 27, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Shield Therapeutics and its competitors. According to the industry distribution chart, Shield Therapeutics ranks #999999 out of 562 companies in the Drug Manufacturers industry.
Is Shield Therapeutics' EV-to-FCF too high?
Shield Therapeutics' current EV-to-FCF is -28.91. Based on the distribution chart, Shield Therapeutics ranks #999999 out of 562 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Shield Therapeutics' EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Shield Therapeutics ranks #999999 out of 562 companies for EV-to-FCF. This places Shield Therapeutics in the lower half of its industry. The industry median EV-to-FCF is 20.11. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.11, based on 562 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Shield Therapeutics and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shield Therapeutics's current EV-to-FCF is -28.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shield Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Shield Therapeutics (STU:1JS) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.09, compared to a current price of €0.07 — trading 24.4% below its estimated fair value. The current EV-to-FCF is -28.91. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Shield Therapeutics (STU:1JS), the current EV-to-FCF is -28.91 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Shield Therapeutics PLC is a commercial-stage specialty pharmaceutical company that delivers ACCRUFeR/FeRACCRU (ferric maltol), a differentiated pharmaceutical product, to address the unmet need for patients suffering from iron deficiency, with or without anemia. The company has launched ACCRUFeR in the U.S. Outside of the U.S., it has licensed the rights to specialty pharmaceutical companies. FeRACCRU is commercialised in the UK, the European Union, and Canada, with marketing rights in Australia and New Zealand. The company's operating segments are: FeRACCRU, which generates the maximum revenue, and PT20. Geographically, it generates maximum revenue from the U.S., and the rest from the Netherlands, Canada, Japan, and South Korea.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:1JS has been successfully added to your 